PDC*lung01

BIOLOGICAL2 trials

Sponsors

PDC line pharma, PDC*line Pharma SAS

Conditions

Non Small Cell Lung CancerNon-small-cell lung cancer

Phase 1

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruitingNCT03970746

PDC*line Pharma SASNon Small Cell Lung Cancer

Start: 2019-09-10End: 2025-12-31Updated: 2025-05-29

An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)

CompletedCTIS2024-517429-24-00

PDC line pharmaNon-small-cell lung cancer

Start: 2020-01-09End: 2025-09-30Target: 64Updated: 2025-06-17

Related Papers

Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer

Cancer Research2024-03-22